Physician profile
Hunter A Hammill
NPI 1992892475
$7,579.12
in general payments reported to CMS, 2019-2025
15 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $917 · 2021: $2,180 · 2022: $841 · 2023: $878 · 2024: $669 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.85 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,969.66 | 2019-2025 | Dovato, Rukobia, Apretude |
| Gilead Sciences, INC. | $1,622.58 | 2019-2025 | Epclusa |
| Theratechnologies INC. | $1,143.97 | 2019-2024 | Egrifta, Trogarzo |
| Janssen Products, LP | $1,062.12 | 2019-2022 | |
| Janssen Biotech, INC. | $530.55 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $510.29 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Emd Serono, INC. | $396.43 | 2019-2025 | |
| Napo Pharmaceuticals INC | $192.45 | 2019-2024 | Mytesi |
| Vbi Vaccine (Delaware) INC. | $35.59 | 2023 | Prehevbrio |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Neurocrine Biosciences, INC. | $20.58 | 2024 | Ingrezza |
| Mylan Specialty L.P. | $17.57 | 2019 | |
| Exact Sciences Corporation | $16.71 | 2024 | Cologuard Collection Kit |
| Davol INC. | $16.67 | 2021 | |
| Mylan Institutional INC. | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Hammill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.